Drug
Argx 213
Argx 213: highest development phase Phase 1, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARGX-213 NCT06968338 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Argx 213 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.